Molecular mechanisms underlying the effects of statins in the central nervous system

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20607-20637

  McFarland, Amelia J ^a   Anoopkumar Dukie, Shailendra ^a   Arora, Devinder S ^a   Grant, Gary D ^a   McDermott, Catherine M ^b   Perkins, Anthony V ^a   Davey, Andrew K ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b BOND UNIVERSITY   (Australia)

Author keywords

Central nervous system (CNS); Cognition; Neuroprotection; Neurotoxicity; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; MEVINOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; COGNITION; DEPRESSION; DOWN REGULATION; DRUG MECHANISM; DRUG PENETRATION; EPILEPSY; HUMAN; MENTAL DISEASE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROFIBROMATOSIS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; UPREGULATION; ANIMAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG EFFECTS; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; STROKE;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; COGNITION; DEPRESSION; EPILEPSY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEURODEGENERATIVE DISEASES; STROKE;

EID: 84910143418     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120607     Document Type: Review

References (165)

1. Parsaik, A.K.; Singh, B.; Hassan, M.M.; Singh, K.; Mascarenhas, S.S.; Williams, M.D.; Lapid, M.I.; Richardson, J.W.; West, C.P.; Rummans, T.A. Statins use and risk of depression: A systematic review and meta-analysis. J. Affect. Disord. 2014, 160, 62-67.
2. Swiger, K.J.; Manalac, R.J.; Blumenthal, R.S.; Blaha, M.J.; Martin, S.S. Statins and cognition: A systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin. Proc. 2013, 88, 1213-1221.
3. Ni Chroinin, D.; Asplund, K.; Asberg, S.; Callaly, E.; Cuadrado-Godia, E.; Diez-Tejedor, E.; di Napoli, M.; Engelter, S.T.; Furie, K.L.; Giannopoulos, S., et al. Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials. Stroke 2013, 44, 448-456.
4. McKinney, J.S.; Kostis, W.J. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke 2012, 43, 2149-2156.
5. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol. 2005, 19, 117-125.
6. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292, 1160-1164.
7. Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34-47.
8. Ginsberg, H.N.; Le, N.A.; Short, M.P.; Ramakrishnan, R.; Desnick, R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J. Clin. Investig. 1987, 80, 1692-1697.
9. Grundy, S. Consensus statement: Role of therapy with “statins” in patients with hypertriglyceridemia. Am. J. Cardiol. 1998, 81, 1B.
10. Greenwood, J.; Steinman, L.; Zamvil, S.S. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat. Rev. Immunol. 2006, 6, 358-370.
11. Gotto, A.M., Jr.; Moon, J. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. Expert Rev. Cardiovasc. Ther. 2010, 8, 1079-1090.
12. Garcia, M.J.; Reinoso, R.F.; Sanchez Navarro, A.; Prous, J.R. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 2003, 25, 457-481.
13. Lennernas, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 2003, 42, 1141-1160.
14. Quion, J.A.V.; Jones, P.H. Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. 1994, 27, 94-103.
15. Davignon, J. Pleiotropic effects of pitavastatin. Br. J. Clin. Pharmacol. 2012, 73, 518-535.
16. Alagona, P., Jr. Pitavastatin: Evidence for its place in treatment of hypercholesterolemia. Core Evid. 2010, 5, 91-105.
17. Beltowski, J.; Wojcicka, G.; Jamroz-Wisniewska, A. Adverse effects of statins—Mechanisms and consequences. Curr. Drug Saf. 2009, 4, 209-228.
18. Kowa Pharmaceuticals America Inc. Livalo (pitavastatin calcium) tablets prescribing information. Available online: http://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf (accessed on 27 August 2014).
19. Holtzman, C.W.; Wiggins, B.S.; Spinler, S.A. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006, 26, 1601-1607.
20. Goard, C.A.; Mather, R.G.; Vinepal, B.; Clendening, J.W.; Martirosyan, A.; Boutros, P.C.; Sharom, F.J.; Penn, L.Z. Differential interactions between statins and P-glycoprotein: Implications for exploiting statins as anticancer agents. Int. J. Cancer 2010, 127, 2936-2948.
21. Kajinami, K.; Takekoshi, N.; Saito, Y. Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. 2003, 21, 199-215.
22. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 2010, 87, 130-133.
23. McKenney, J.M. Pharmacologic characteristics of statins. Clin. Cardiol. 2003, 26, 32-38.
24. Dietschy, J.M.; Turley, S.D. Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45, 1375-1397.
25. Dietschy, J.M.; Turley, S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12, 105-112.
26. Nieweg, K.; Schaller, H.; Pfrieger, F.W. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 2009, 109, 125-134.
27. Orth, M.; Bellosta, S. Cholesterol: Its regulation and role in central nervous system disorders. Cholesterol 2012, 2012, 19.
28. Lutjohann, D.; Stroick, M.; Bertsch, T.; Kuhl, S.; Lindenthal, B.; Thelen, K.; Andersson, U.; Bjorkhem, I.; von Bergmann, K.; Fassbender, K. High doses of simvastatin, pravastatin and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004, 69, 431-438.
29. Thelen, K.M.; Rentsch, K.M.; Gutteck, U.; Heverin, M.; Olin, M.; Andersson, U.; von Eckardstein, A.; Björkhem, I.; Lütjohann, D. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 2006, 316, 1146-1152.
30. Andersson, M.; Elmberger, P.O.; Edlund, C.; Kristensson, K.; Dallner, G. Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS Lett. 1990, 269, 15-18.
31. Bjoandrkhem, I.; Heverin, M.; Leoni, V.; Meaney, S.; Diczfalusy, U. Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. 2006, 114, 43-49.
32. Cibičková, L. Statins and their influence on brain cholesterol. J. Clin. Lipidol. 2011, 5, 373-379.
33. Vega, G.L.; Weiner, M.F.; Lipton, A.M.; Von Bergmann, K.; Lutjohann, D.; Moore, C.; Svetlik, D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 2003, 60, 510-515.
34. Simons, M.; Schwarzler, F.; Lutjohann, D.; von Bergmann, K.; Beyreuther, K.; Dichgans, J.; Wormstall, H.; Hartmann, T.; Schulz, J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 2002, 52, 346-350.
35. Fassbender, K.; Stroick, M.; Bertsch, T.; Ragoschke, A.; Kuehl, S.; Walter, S.; Walter, J.; Brechtel, K.; Muehlhauser, F.; von Bergmann, K. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002, 59, 1257-1258.
36. Serrano-Pozo, A.; Vega, G.L.; Lutjohann, D.; Locascio, J.J.; Tennis, M.K.; Deng, A.; Atri, A.; Hyman, B.T.; Irizarry, M.C.; Growdon, J.H. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis. Assoc. Disord. 2010, 24, 220-226.
37. Locatelli, S.; Lutjohann, D.; Schmidt, H.H.; Otto, C.; Beisiegel, U.; von Bergmann, K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch. Neurol. 2002, 59, 213-216.
38. Thelen, K.M.; Lutjohann, D.; Vesalainen, R.; Janatuinen, T.; Knuuti, J.; von Bergmann, K.; Lehtimaki, T.; Laaksonen, R. Effect of pravastatin on plasma sterols and oxysterols in men. Eur. J. Clin. Pharmacol. 2006, 62, 9-14.
39. Thelen, K.M.; Laaksonen, R.; Paiva, H.; Lehtimaki, T.; Lutjohann, D. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J. Clin. Pharmacol. 2006, 46, 812-816.
40. Johnson-Anuna, L.N.; Eckert, G.P.; Keller, J.H.; Igbavboa, U.; Franke, C.; Fechner, T.; Schubert-Zsilavecz, M.; Karas, M.; Muller, W.E.; Wood, W.G. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 2005, 312, 786-793.
41. Botti, R.E.; Triscari, J.; Pan, H.Y.; Zayat, J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol. 1991, 14, 256-261.
42. Niemi, M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007, 8, 787-802.
43. Tamai, I.; Takanaga, H.; Maeda, H.; Ogihara, T.; Yoneda, M.; Tsuji, A. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm. Res. 1995, 12, 1727-1732.
44. Rojas-Fernandez, C.H.; Cameron, J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother. 2012, 46, 549-557.
45. Wagstaff, L.R.; Mitton, M.W.; Arvik, B.M.; Doraiswamy, P.M. Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23, 871-880.
46. Mandas, A.; Congiu, M.G.; Abete, C.; Dessi, S.; Manconi, P.E.; Musio, M.; Columbu, S.; Racugno, W. Cognitive decline and depressive symptoms in late-life are associated with statin use: Evidence from a population-based study of Sardinian old people living in their own home. Neurol. Res. 2014, 36, 247-254.
47. Sparks, D.L.; Kryscio, R.J.; Sabbagh, M.N.; Connor, D.J.; Sparks, L.M.; Liebsack, C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 2008, 5, 416-421.
48. Jick, H.; Zornberg, G.L.; Jick, S.S.; Seshadri, S.; Drachman, D.A. Statins and the risk of dementia. Lancet 2000, 356, 1627-1631.
49. Wolozin, B.; Wang, S.; Li, N.-C.; Lee, A.; Lee, T.; Kazis, L. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 2007, 5, 1-11.
50. Bettermann, K.; Arnold, A.M.; Williamson, J.; Rapp, S.; Sink, K.; Toole, J.F.; Carlson, M.C.; Yasar, S.; DeKosky, S.; Burke, G.L. Statins, risk of dementia and cognitive function: Secondary analysis of the ginkgo evaluation of memory study. J. Stroke Cerebrovasc. Dis. 2012, 21, 436-444.
51. Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; Simes, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376, 1670-1681.
52. Anstey, K.J.; Lipnicki, D.M.; Low, L.-F. Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am. J. Geriatr. Psychiatry 2008, 16, 343-354.
53. Dufouil, C.; Richard, F.; Fievet, N.; Dartigues, J.F.; Ritchie, K.; Tzourio, C.; Amouyel, P.; Alperovitch, A. APOE genotype, cholesterol level, lipid-lowering treatment and dementia: The three-city study. Neurology 2005, 64, 1531-1538.
54. Yaffe, K.; Barrett-Connor, E.; Lin, F.; Grady, D. Serum lipoprotein levels, statin use and cognitive function in older women. Arch. Neurol. 2002, 59, 378-384.
55. Mans, R.A.; McMahon, L.L.; Li, L. Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience 2012, 202, 1-9.
56. Kotti, T.J.; Ramirez, D.M.; Pfeiffer, B.E.; Huber, K.M.; Russell, D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 2006, 103, 3869-3874.
57. Schulz, J.G.; Bosel, J.; Stoeckel, M.; Megow, D.; Dirnagl, U.; Endres, M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J. Neurochem. 2004, 89, 24-32.
58. Ekdahl, C.T.; Claasen, J.H.; Bonde, S.; Kokaia, Z.; Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA 2003, 100, 13632-13637.
59. Monje, M.L.; Toda, H.; Palmer, T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302, 1760-1765.
60. Robin, N.C.; Agoston, Z.; Biechele, T.L.; James, R.G.; Berndt, J.D.; Moon, R.T. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/β-catenin signaling. Stem Cell Rep. 2014, 2, 9-17.
61. Lu, D.; Qu, C.; Goussev, A.; Jiang, H.; Lu, C.; Schallert, T.; Mahmood, A.; Chen, J.; Li, Y.; Chopp, M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J. Neurotrauma 2007, 24, 1132-1146.
62. Wu, H.; Lu, D.; Jiang, H.; Xiong, Y.; Qu, C.; Li, B.; Mahmood, A.; Zhou, D.; Chopp, M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J. Neurotrauma 2008, 25, 130-139.
63. Probst, A.; Langui, D.; Ulrich, J. Alzheimer’s disease: A description of the structural lesions. Brain Pathol. 1991, 1, 229-239.
64. Wolozin, B.; Kellman, W.; Ruosseau, P.; Celesia, G.G.; Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57, 1439-1443.
65. Haag, M.D.M.; Hofman, A.; Koudstaal, P.J.; Stricker, B.H.C.; Breteler, M.M.B. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J. Neurol. Neurosur. Psychiatry 2009, 80, 13-17.
66. Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; von Bergmann, K., et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 5856-5861.
67. Kurata, T.; Miyazaki, K.; Kozuki, M.; Panin, V.-L.; Morimoto, N.; Ohta, Y.; Nagai, M.; Ikeda, Y.; Matsuura, T.; Abe, K. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011, 1371, 161-170.
68. Tramontina, A.C.; Wartchow, K.M.; Rodrigues, L.; Biasibetti, R.; Quincozes-Santos, A.; Bobermin, L.; Tramontina, F.; Goncalves, C.A. The neuroprotective effect of two statins: Simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats. J. Neural. Transm. 2011, 118, 1641-1649.
69. Eckert, G.P.; Hooff, G.P.; Strandjord, D.M.; Igbavboa, U.; Volmer, D.A.; Muller, W.E.; Wood, W.G. Regulation of the brain isoprenoids farnesyl-and geranyl-geranylpyrophosphate is altered in male Alzheimer patients. Neurobiol. Dis. 2009, 35, 251-257.
70. Pedrini, S.; Carter, T.L.; Prendergast, G.; Petanceska, S.; Ehrlich, M.E.; Gandy, S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2005, 2, e18.
71. Shinohara, M.; Sato, N.; Kurinami, H.; Takeuchi, D.; Takeda, S.; Shimamura, M.; Yamashita, T.; Uchiyama, Y.; Rakugi, H.; Morishita, R. Reduction of brain β-amyloid (Aβ) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Aβ clearance. J. Biol. Chem. 2010, 285, 22091-22102.
72. Ostrowski, S.M.; Wilkinson, B.L.; Golde, T.E.; Landreth, G. Statins reduce amyloid-β production through inhibition of protein isoprenylation. J. Biol. Chem. 2007, 282, 26832-26844.
73. Hosaka, A.; Araki, W.; Oda, A.; Tomidokoro, Y.; Tamaoka, A. Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. Neurochem. Res. 2013, 38, 589-600.
74. Pac-Soo, C.; Lloyd, D.G.; Vizcaychipi, M.P.; Ma, D. Statins: The role in the treatment and prevention of Alzheimer’s neurodegeneration. J. Alzheimers Dis. 2011, 27, 1-10.
75. Clarke, R.M.; O’Connell, F.; Lyons, A.; Lynch, M.A. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β1-42 in the rat hippocampus in vivo. Neuropharmacology 2007, 52, 136-145.
76. Cordle, A.; Landreth, G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J. Neurosci. 2005, 25, 299-307.
77. Asahi, M.; Huang, Z.; Thomas, S.; Yoshimura, S.-I.; Sumii, T.; Mori, T.; Qiu, J.; Amin-Hanjani, S.; Huang, P.L.; Liao, J.K. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J. Cerebr. Blood Flow Metab. 2005, 25, 722-729.
78. Barone, E.; Cenini, G.; di Domenico, F.; Martin, S.; Sultana, R.; Mancuso, C.; Murphy, M.P.; Head, E.; Butterfield, D.A. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action. Pharmacol. Res. 2011, 63, 172-180.
79. Meske, V.; Albert, F.; Richter, D.; Schwarze, J.; Ohm, T.G. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: Implications for Alzheimer’s disease. Eur. J. Neurosci. 2003, 17, 93-102.
80. Bi, X.; Baudry, M.; Liu, J.; Yao, Y.; Fu, L.; Brucher, F.; Lynch, G. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J. Biol. Chem. 2004, 279, 48238-48245.
81. Piermartiri, T.C.; Figueiredo, C.P.; Rial, D.; Duarte, F.S.; Bezerra, S.C.; Mancini, G.; de Bem, A.F.; Prediger, R.D.; Tasca, C.I. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: Evidence for dissociation between cognitive deficits and neuronal damage. Exp. Neurol. 2010, 226, 274-284.
82. Tong, X.K.; Nicolakakis, N.; Fernandes, P.; Ongali, B.; Brouillette, J.; Quirion, R.; Hamel, E. Simvastatin improves cerebrovascular function and counters soluble amyloid-β, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 2009, 35, 406-414.
83. Tong, X.K.; Lecrux, C.; Rosa-Neto, P.; Hamel, E. Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. J. Neurosci. 2012, 32, 4705-4715.
84. Tamboli, I.Y.; Barth, E.; Christian, L.; Siepmann, M.; Kumar, S.; Singh, S.; Tolksdorf, K.; Heneka, M.T.; Lutjohann, D.; Wunderlich, P., et al. Statins promote the degradation of extracellular amyloid β-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J. Biol. Chem. 2010, 285, 37405-37414.
85. Urano, Y.; Hayashi, I.; Isoo, N.; Reid, P.C.; Shibasaki, Y.; Noguchi, N.; Tomita, T.; Iwatsubo, T.; Hamakubo, T.; Kodama, T. Association of active γ-secretase complex with lipid rafts. J. Lipid Res. 2005, 46, 904-912.
86. Phani, S.; Loike, J.D.; Przedborski, S. inflammation in Parkinson’s disease. Parkinsonism Relat. Disord. 2012, 18, S207-S209.
87. Lee, Y.-C.; Lin, C.-H.; Wu, R.-M.; Lin, M.-S.; Lin, J.-W.; Chang, C.-H.; Lai, M.-S. Discontinuation of statin therapy associates with Parkinson disease. A population-based study. Neurology 2013, 81, 410-416.
88. Tison, F.; Nègre-Pagès, L.; Meissner, W.G.; Dupouy, S.; Li, Q.; Thiolat, M.-L.; Thiollier, T.; Galitzky, M.; Ory-Magne, F.; Milhet, A., et al. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism Relat. Disord. 2013, 19, 416-421.
89. Xu, Y.Q.; Long, L.; Yan, J.Q.; Wei, L.; Pan, M.Q.; Gao, H.M.; Zhou, P.; Liu, M.; Zhu, C.S.; Tang, B.S., et al. Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses. CNS Neurosci. Ther. 2013, 19, 170-177.
90. Selley, M.L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005, 1037, 1-6.
91. Kumar, A.; Sharma, N.; Gupta, A.; Kalonia, H.; Mishra, J. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res. 2012, 1471, 13-22.
92. Yan, J.; Xu, Y.; Zhu, C.; Zhang, L.; Wu, A.; Yang, Y.; Xiong, Z.; Deng, C.; Huang, X.F.; Yenari, M.A., et al. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: The association with anti-inflammatory responses. PLoS One 2011, 6, e20945.
93. Ghosh, A.; Roy, A.; Matras, J.; Brahmachari, S.; Gendelman, H.E.; Pahan, K. Simvastatin inhibits the activation of p21Ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson’s disease. J. Neurosci. 2009, 29, 13543-13556.
94. Lassmann, H.; Brück, W.; Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 2001, 7, 115-121.
95. Chataway, J.; Schuerer, N.; Alsanousi, A.; Chan, D.; MacManus, D.; Hunter, K.; Anderson, V.; Bangham, C.R.M.; Clegg, S.; Nielsen, C., et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet 2014, 383, 2213-2221.
96. Paintlia, A.S.; Paintlia, M.K.; Singh, A.K.; Orak, J.K.; Singh, I. Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia 2010, 58, 1669-1685.
97. Miron, V.E.; Zehntner, S.P.; Kuhlmann, T.; Ludwin, S.K.; Owens, T.; Kennedy, T.E.; Bedell, B.J.; Antel, J.P. Statin therapy inhibits remyelination in the central nervous system. Am. J. Pathol. 2009, 174, 1880-1890.
98. Pan, H.C.; Yang, D.Y.; Ou, Y.C.; Ho, S.P.; Cheng, F.C.; Chen, C.J. Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury. Neurosurgery 2010, 67, 376-388.
99. Miron, V.E.; Rajasekharan, S.; Jarjour, A.A.; Zamvil, S.S.; Kennedy, T.E.; Antel, J.P. Simvastatin regulates oligodendroglial process dynamics and survival. Glia 2007, 55, 130-143.
100. Klopfleisch, S.; Merkler, D.; Schmitz, M.; Klöppner, S.; Schedensack, M.; Jeserich, G.; Althaus, H.H.; Brück, W. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J. Neurosci. 2008, 28, 13609-13614.
101. Saher, G.; Brugger, B.; Lappe-Siefke, C.; Mobius, W.; Tozawa, R.; Wehr, M.C.; Wieland, F.; Ishibashi, S.; Nave, K.A. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 2005, 8, 468-475.
102. Stanislaus, R.; Pahan, K.; Singh, A.K.; Singh, I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 1999, 269, 71-74.
103. Paintlia, A.S.; Paintlia, M.K.; Singh, A.K.; Singh, I. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol. Pharmacol. 2008, 73, 1381-1393.
104. Dunn, S.E.; Youssef, S.; Goldstein, M.J.; Prod’homme, T.; Weber, M.S.; Zamvil, S.S.; Steinman, L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 2006, 203, 401-412.
105. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420, 78-84.
106. Aktas, O.; Waiczies, S.; Smorodchenko, A.; Dorr, J.; Seeger, B.; Prozorovski, T.; Sallach, S.; Endres, M.; Brocke, S.; Nitsch, R., et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197, 725-733.
107. Sim, F.J.; Lang, J.K.; Ali, T.A.; Roy, N.S.; Vates, G.E.; Pilcher, W.H.; Goldman, S.A. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia 2008, 56, 954-962.
108. North, K.; Hyman, S.; Barton, B. Cognitive deficits in neurofibromatosis 1. J. Child. Neurol. 2002, 17, 605-612.
109. Li, W.; Cui, Y.; Kushner, S.A.; Brown, R.A.M.; Jentsch, J.D.; Frankland, P.W.; Cannon, T.D.; Silva, A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005, 15, 1961-1967.
110. Acosta, M.T.; Kardel, P.G.; Walsh, K.S.; Rosenbaum, K.N.; Gioia, G.A.; Packer, R.J. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: Phase I study. Pediatr. Neurol. 2011, 45, 241-245.
111. Van der Vaart, T.; Plasschaert, E.; Rietman, A.B.; Renard, M.; Oostenbrink, R.; Vogels, A.; de Wit, M.-C.Y.; Descheemaeker, M.-J.; Vergouwe, Y.; Catsman-Berrevoets, C.E., et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): A randomised, placebo-controlled trial. Lancet Neurol. 2013, 12, 1076-1083.
112. Cappellari, M.; Bovi, P.; Moretto, G.; Zini, A.; Nencini, P.; Sessa, M.; Furlan, M.; Pezzini, A.; Orlandi, G.; Paciaroni, M. The THRombolysis and STatins (THRaST) study. Neurology 2013, 80, 655-661.
113. Flint, A.C.; Kamel, H.; Navi, B.B.; Rao, V.A.; Faigeles, B.S.; Conell, C.; Klingman, J.G.; Hills, N.K.; Nguyen-Huynh, M.; Cullen, S.P., et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 2012, 78, 1678-1683.
114. Flint, A.C.; Kamel, H.; Navi, B.B.; Rao, V.A.; Faigeles, B.S.; Conell, C.; Klingman, J.G.; Sidney, S.; Hills, N.K.; Sorel, M., et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012, 43, 147-154.
115. Cappellari, M.; Deluca, C.; Tinazzi, M.; Tomelleri, G.; Carletti, M.; Fiaschi, A.; Bovi, P.; Moretto, G. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J. Neurol. Sci. 2011, 308, 128-134.
116. Endres, M.; Laufs, U.; Liao, J.K.; Moskowitz, M.A. Targeting eNOS for stroke protection. Trends Neurosci. 2004, 27, 283-289.
117. Endres, M.; Laufs, U.; Huang, Z.; Nakamura, T.; Huang, P.; Moskowitz, M.A.; Liao, J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 1998, 95, 8880-8885.
118. Sawada, N.; Liao, J.K. Targeting eNOS and beyond: Emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev. Neurother. 2009, 9, 1171-1186.
119. Gasche, Y.; Copin, J.-C.; Sugawara, T.; Fujimura, M.; Chan, P.H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cerebr. Blood Flow Metab. 2001, 21, 1393-1400.
120. Woo, M.-S.; Park, J.-S.; Choi, I.-Y.; Kim, W.-K.; Kim, H.-S. Inhibition of MMP-3 or-9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem. 2008, 106, 770-780.
121. Liu, X.S.; Zhang, Z.G.; Zhang, L.; Morris, D.C.; Kapke, A.; Lu, M.; Chopp, M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cerebr. Blood Flow Metab. 2006, 26, 787-796.
122. Wang, S.; Lee, S.-R.; Guo, S.-Z.; Kim, W.J.; Montaner, J.; Wang, X.; Lo, E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006, 37, 1910-1912.
123. Hong, H.; Zeng, J.-S.; Kreulen, D.L.; Kaufman, D.I.; Chen, A.F. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H2210-H2215.
124. Erdös, B.; Snipes, J.A.; Tulbert, C.D.; Katakam, P.; Miller, A.W.; Busija, D.W. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am. J. Physiol-Heart C 2006, 290, H1264-H1270.
125. Ma, T.; Zhao, Y.; Kwak, Y.-D.; Yang, Z.; Thompson, R.; Luo, Z.; Xu, H.; Liao, F.-F. Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via Rho-ROCK signaling. J. Neurosci. 2009, 29, 11226-11236.
126. Etminan, M.; Samii, A.; Brophy, J.M. Statin use and risk of epilepsy: A nested case-control study. Neurology 2010, 75, 1496-1500.
127. Piermartiri, T.C.; Vandresen-Filho, S.; de Araujo Herculano, B.; Martins, W.C.; Dal’agnolo, D.; Stroeh, E.; Carqueja, C.L.; Boeck, C.R.; Tasca, C.I. Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotox. Res. 2009, 16, 106-115.
128. Lee, J.K.; Won, J.S.; Singh, A.K.; Singh, I. Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. Neurosci. Lett. 2008, 440, 260-264.
129. Ponce, J.; de la Ossa, N.P.; Hurtado, O.; Millan, M.; Arenillas, J.F.; Dávalos, A.; Gasull, T. Simvastatin reduces the association of NMDA receptors to lipid rafts: A cholesterol-mediated effect in neuroprotection. Stroke 2008, 39, 1269-1275.
130. Zacco, A.; Togo, J.; Spence, K.; Ellis, A.; Lloyd, D.; Furlong, S.; Piser, T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 2003, 23, 11104-11111.
131. Ramirez, C.; Tercero, I.; Pineda, A.; Burgos, J.S. Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J. Alzheimers Dis. 2011, 24, 161-174.
132. Citraro, R.; Chimirri, S.; Aiello, R.; Gallelli, L.; Trimboli, F.; Britti, D.; de Sarro, G.; Russo, E. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 2014, 55, 1284-1291.
133. Yang, C.C.; Jick, S.S.; Jick, H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch. Intern. Med. 2003, 163, 1926-1932.
134. Young-Xu, Y.; Chan, K.A.; Liao, J.K.; Ravid, S.; Blatt, C.M. Long-term statin use and psychological well-being. J. Am. Coll. Cardiol. 2003, 42, 690-697.
135. Feng, L.; Tan, C.H.; Merchant, R.A.; Ng, T.P. Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H2 receptor antagonists in community-dwelling older persons: Cross-sectional analysis of a population-based cohort. Drugs Aging 2008, 25, 795-805.
136. Kim, J.M.; Stewart, R.; Kang, H.J.; Bae, K.Y.; Kim, S.W.; Shin, I.S.; Kim, J.T.; Park, M.S.; Cho, K.H.; Yoon, J.S. A prospective study of statin use and poststroke depression. J. Clin. Psychopharmacol. 2014, 34, 72-79.
137. Otte, C.; Zhao, S.; Whooley, M.A. Statin use and risk of depression in patients with coronary heart disease: Longitudinal data from the Heart and Soul Study. J. Clin. Psychiatry 2012, 73, 610-615.
138. Stafford, L.; Berk, M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: Proof of concept for the inflammatory and oxidative hypotheses of depression? J. Clin. Psychiatry 2011, 72, 1229-1235.
139. Chuang, C.S.; Yang, T.Y.; Muo, C.H.; Su, H.L.; Sung, F.C.; Kao, C.H. Hyperlipidemia, statin use and the risk of developing depression: A nationwide retrospective cohort study. Gen. Hosp. Psychiatry 2014, 36, 497-501.
140. Agostini, J.V.; Tinetti, M.E.; Han, L.; McAvay, G.; Foody, J.M.; Concato, J. Effects of statin use on muscle strength, cognition and depressive symptoms in older adults. J. Am. Geriatr. Soc. 2007, 55, 420-425.
141. Feng, L.; Yap, K.B.; Kua, E.H.; Ng, T.P. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol. Drug Saf. 2010, 19, 942-948.
142. Al Badarin, F.J.; Spertus, J.A.; Gosch, K.L.; Buchanan, D.M.; Chan, P.S. Initiation of statin therapy after acute myocardial infarction is not associated with worsening depressive symptoms: Insights from the Prospective Registry Evaluating Outcomes After Myocardial Infarctions: Events and Recovery (PREMIER) and Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status (TRIUMPH) registries. Am. Heart J. 2013, 166, 879-886.
143. Lin, P.Y.; Chang, A.Y.; Lin, T.K. Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress. Pharmacol. Biochem. Behav. 2014, 124, 174-179.
144. Ludka, F.K.; Zomkowski, A.D.E.; Cunha, M.P.; Dal-Cim, T.; Zeni, A.L.B.; Rodrigues, A.L.S.; Tasca, C.I. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur. Neuropsychopharm. 2013, 23, 400-412.
145. Mansi, I.; Frei, C.R.; Pugh, M.J.; Mortensen, E.M. Psychologic disorders and statin use: A propensity score-matched analysis. Pharmacotherapy 2013, 33, 615-626.
146. Nielsen, S.F.; Nordestgaard, B.G.; Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 2012, 367, 1792-1802.
147. Shepherd, J.; Blauw, G.J.; Murphy, M.B.; Bollen, E.L.; Buckley, B.M.; Cobbe, S.M.; Ford, I.; Gaw, A.; Hyland, M.; Jukema, J.W. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002, 360, 1623-1630.
148. Dale, K.M.; Coleman, C.I.; Henyan, N.N.; Kluger, J.; White, C. Statins and cancer risk: A meta-analysis. JAMA 2006, 295, 74-80.
149. Mihaylova, B.; Emberson, J.; Blackwell, L.; Keech, A.; Simes, J.; Barnes, E.H.; Voysey, M.; Gray, A.; Collins, R.; Baigent, C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380, 581-590.
150. Thibault, A.; Samid, D.; Tompkins, A.C.; Figg, W.D.; Cooper, M.R.; Hohl, R.J.; Trepel, J.; Liang, B.; Patronas, N.; Venzon, D.J. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 1996, 2, 483-491.
151. Larner, J.; Jane, J.; Laws, E.; Packer, R.; Myers, C.; Shaffrey, M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol. 1998, 21, 579-583.
152. Murakami, M.; Goto, T.; Saito, Y.; Goto, S.; Kochi, M.; Ushio, Y. The inhibitory effect of simvastatin on growth in malignant gliomas—With special reference to its local application with fibrin glue spray in vivo. Int. J. Oncol. 2001, 19, 525-531.
153. Maltese, W.A.; Defendini, R.; Green, R.A.; Sheridan, K.M.; Donley, D.K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Investig. 1985, 76, 1748-1754.
154. Dimitroulakos, J.; Ye, L.Y.; Benzaquen, M.; Moore, M.J.; Kamel-Reid, S.; Freedman, M.H.; Yeger, H.; Penn, L.Z. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications. Clin. Cancer Res. 2001, 7, 158-167.
155. Prasanna, P.; Thibault, A.; Liu, L.; Samid, D. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem. 1996, 66, 710-716.
156. Yanae, M.; Tsubaki, M.; Satou, T.; Itoh, T.; Imano, M.; Yamazoe, Y.; Nishida, S. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J. Exp. Clin. Cancer Res. 2011, 30, 74.
157. Crick, D.C.; Andres, D.A.; Danesi, R.; Macchia, M.; Waechter, C.J. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 1998, 70, 2397-2405.
158. Marcuzzi, A.; Zanin, V.; Piscianz, E.; Tricarico, P.M.; Vuch, J.; Girardelli, M.; Monasta, L.; Bianco, A.M.; Crovella, S. Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line. Int. J. Dev. Neurosci. 2012, 30, 451-456.
159. Déry, M.A.; Rousseau, G.; Benderdour, M.; Beaumont, E. Atorvastatin prevents early apoptosis after thoracic spinal cord contusion injury and promotes locomotion recovery. Neurosci. Lett. 2009, 453, 73-76.
160. Pannu, R.; Christie, D.K.; Barbosa, E.; Singh, I.; Singh, A.K. Post-trauma lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection and promotes locomotor recovery following spinal cord injury. J. Neurochem. 2007, 101, 182-200.
161. Pannu, R.; Barbosa, E.; Singh, A.K.; Singh, I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J. Neurosci. Res. 2005, 79, 340-350.
162. Han, X.; Yang, N.; Cui, Y.; Xu, Y.; Dang, G.; Song, C. Simvastatin mobilizes bone marrow stromal cells migrating to injured areas and promotes functional recovery after spinal cord injury in the rat. Neurosci. Lett. 2012, 521, 136-141.
163. Han, X.; Yang, N.; Xu, Y.; Zhu, J.; Chen, Z.; Liu, Z.; Dang, G.; Song, C. Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF. Neurosci. Lett. 2011, 487, 255-259.
164. Kahveci, R.; Gökçe, E.C.; Gürer, B.; Gökçe, A.; Kisa, U.; Cemil, D.B.; Sargon, M.F.; Kahveci, F.O.; Aksoy, N.; Erdoğan, B. Neuroprotective effects of rosuvastatin against traumatic spinal cord injury in rats. Eur. J. Pharmacol. 2014, 741, 45-54.
165. Mann, C.M.; Lee, J.H.T.; Hillyer, J.; Stammers, A.M.T.; Tetzlaff, W.; Kwon, B.K. Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury. Exp. Neurol. 2010, 221, 285-295.